Drug intelligence / Profile preview

FOLFOXA

Development stage: Unknown
Lead developer: Brown University Oncology Group
Modality: Small Molecules
Administration: Intravenous

Overview

FOLFOXA is a chemotherapy regimen under investigation for locally advanced pancreatic cancer. It combines nab-paclitaxel (Abraxane), oxaliplatin, leucovorin, and 5-fluorouracil (5-FU). Preliminary data suggest that FOLFOXA may offer comparable or superior efficacy to FOLFIRINOX, another common regimen for pancreatic cancer, while potentially being better tolerated. The regimen involves intravenous administration of its components over a 14-day cycle.

Other names: FOLFOX-A

Targets

TS (Thymidylate synthase)DNA

Beyond the preview

Go deeper on FOLFOXA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FOLFOXA.

Explore the full profile